R. Fischer - Concepedia

Author

R. Fischer

University Medical Center Freiburg

Also Known As

R Fischer, R Paul Fischer, R. Fischer, R. PAUL FISCHER, R. Paul Fischer

Publications

531

Citations

H-Index

Concepts

All Affiliations

University Medical Center Freiburg University of Freiburg The University of Texas Southwestern Medical Center

About

R. Fischer is an author at University Medical Center Freiburg specializing in cancer research, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	47
2	Pathology	2	2	34
3	Pharmacology	2	2	25
4	Cancer Therapeutics	2	2	25
5	Immunology	1	1	22

R. Fischer

Publications

391

Citations

H-Index

Page 1

	Year	Citations
Commercial Tattooing as a Potentially Important Source of Hepatitis C Infection Robert W. Haley, R. Fischer Medicine	2001	152
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study Beate Schultheis, Gunnar Folprecht, Jan Kuhlmann, Annals of Oncology	2013	90
The Tattooing Paradox Robert W. Haley, R. Fischer Archives of Internal Medicine	2003	42
Effect of nucleotides on the cytosolic free calcium activity and inositol phosphate formation in human glomerular epithelial cells Hermann Pavenstädt, M. Späth, Günther Schlunck, British Journal of Pharmacology	1992	34
Impaired cytokine production in whole blood cell cultures from patients with colorectal carcinomas as compared to benign colorectal tumors and controls Ursula Elsässer‐Beile, S. von Kleist, R. Fischer, Journal of Clinical Laboratory Analysis	1992	26
Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas Ursula Elsässer‐Beile, S. von Kleist, R. Fischer, Journal of Cancer Research and Clinical Oncology Urological ResearchUrologyImpaired Cytokine ProductionGenitourinary CancerMalignant Disease	1993	22
Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer. Beate Schultheis, Gunnar Folprecht, Jan Kuhlmann, Journal of Clinical Oncology Gastrointestinal OncologyMedicineCrc PtsMetronomic TherapyPharmacology	2011	13
Abstract A212: First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: Results of a dose escalation study. K. Mross, R. Fischer, Heike Richly, Molecular Cancer Therapeutics PathologyImmunotherapeuticsPd MarkersTumor BiologyPre-clinical Pharmacology	2011	12

Page 1